NCT04851613: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received 1 to 2 prior lines of systemic treatments (adjuvant therapy included) – see trial for details
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease; Patients with prior exposure to Faslodex/fulvestrant or other selective estrogen receptor degraders (SERDs), or any PI3K/AKT/mTOR inhibitors (e.g. Piqray/alpelisib)

Comments are closed.

Up ↑